PGNY Progyny


From Benzinga Pro
Why Jim Cramer Likes Progyny
19 Nov 21
Long Ideas, Media, Trading Ideas
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Lemonade, Inc. (NYSE: LMND) is down so low. He recommends holding onto the stock for a little bit more time.
Progyny: Q3 Earnings Insights
4 Nov 21
Progyny (NASDAQ:PGNY) reported its Q3 earnings results on Thursday, November 4, 2021 at 04:05 PM. Here's what investors need to know about the announcement.
Progyny Q3 EPS $0.17 Beats $0.06 Estimate, Sales $122.30M Miss $125.45M Estimate
4 Nov 21
Earnings, News
Progyny (NASDAQ:PGNY) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.06 by 183.33 percent. This is a 240 percent increase over earnings of $0.05 per share from the same
12 Health Care Stocks Moving In Thursday's After-Market Session
4 Nov 21
Earnings Scheduled For November 4, 2021
4 Nov 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly earnings at $0.91 per share on revenue of $4.45 billion.
Where Progyny Stands With Analysts
30 Sep 21
Analyst Ratings
Progyny (NASDAQ:PGNY) has observed the following analyst ratings within the last quarter:
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
30 Sep 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Berenberg Initiates Coverage On Progyny with Buy Rating, Announces Price Target of $81
30 Sep 21
News, Price Target, Initiation, Analyst Ratings
Berenberg initiates coverage on Progyny (NASDAQ:PGNY) with a Buy rating and announces Price Target of $81.
EVP And General Counsel Of Progyny Trades $1.85 Million In Company Stock
29 Sep 21
News, Insider Trades, Trading Ideas
Jennifer Bealer, EVP And General Counsel at Progyny (NASDAQ:PGNY), made a large buy and sell of company shares on September 24, according to a new SEC filing.
Barclays Maintains Overweight on Progyny, Raises Price Target to $80
28 Sep 21
News, Price Target, Analyst Ratings
Barclays analyst Sarah James maintains Progyny (NASDAQ:PGNY) with a Overweight and raises the price target from $72 to $80.